The Ova Antigen Delivery Reagent has been developed for efficient in vitro targeting of ovalbumin to antigen-presenting cells (APCs), for example, DCs. The reagent consists of a monoclonal anti-biotin antibody conjugated to ovalbumin and FITC. In combination with an appropriate biotinylated anti-receptor antibody, any desired antigen uptake receptor can be targeted.
The Antigen Delivery Module Set comprises all the reagents that are required for the isolation of DCs, antigen delivery, and subsequent analysis of antigen presentation.
Related products for Ova Antigen Delivery Module Set
The Ova Antigen Delivery Reagent has been developed for efficient in vitro targeting of ovalbumin to antigen-presenting cells (APCs), for example, DCs. The reagent consists of a monoclonal anti-biotin antibody conjugated to ovalbumin and FITC. In combination with an appropriate biotinylated anti-receptor antibody, any desired antigen uptake receptor can be targeted.
The Antigen Delivery Module Set comprises all the reagents that are required for the isolation of DCs, antigen delivery, and subsequent analysis of antigen presentation.
Antigen targeting to APCs via specific receptors has been used to induce effective antigen-specific T cell responses.1–5 This allows the functional characterization of new receptors on APCs for comparison with well-characterized ones, such as CD205 (DEC205) or DCIR2 (33D1).
The Ova Antigen Delivery Reagent features efficient and straightforward targeting of ovalbumin to APCs and is a powerful tool for:
- Caminschi, I. et al. (2008) The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112: 3264-3273
- Dudziak, D. et al. (2007) Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111
- Mouriès, J. et al. (2008) Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 112: 3713-3722
- Bonifaz, L. et al. (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196: 1627-1638
You have previously chosen International as your location.
What do you want to do?